Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06002503 · ClinicalTrials.gov registry record · Phase 1
Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection
A Phase 1 study of Vaccine Reaction, sponsored by PharmaJet.
- Active
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06002503: Active Phase 1 study of Vaccine Reaction, sponsored by PharmaJet.
NCT06002503 is a Phase 1 study of Vaccine Reaction that is active but no longer recruiting, run by PharmaJet. The registered enrollment target is 46 participants, below the 132-participant average among 4 other Vaccine Reaction trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06002503, a Phase 1 study of Vaccine Reaction, is active but no longer recruiting, sponsored by PharmaJet.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the safety and reactogenicity of a VEE DNA Vaccine candidate delivered by either intramuscular or intradermal jet injection. The main question it aims to answer is: • Is the VEE DNA Vaccine candidate safe Participants will: * Receive the VEE DNA Vaccine candidate by either intramuscular or intradermal jet injection * Provide blood and urine samples * Complete ECGs * Complete physical exams * Complete diaries
Conditions Studied
Interventions
- DRUG Venezuelan Equine Encephalitis DNA Vaccine
- DEVICE PharmaJet Stratis Needle-free Injection System
- DEVICE PharmaJet Tropis Needle-free Injection System
Study Locations (1)
Ohio
- Velocity Clinical Research - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2025-05-31 |
| Phase | Phase 1 |
What the registry record for NCT06002503 still lists
NCT06002503 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 132-participant average among 4 other Vaccine Reaction trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Vaccine Reaction appearing as the primary indexed condition, and to 3 interventions - of which Venezuelan Equine Encephalitis DNA Vaccine is the first listed.
NCT06002503 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06002503 about?
NCT06002503 is a clinical study titled "Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection". The goal of this clinical trial is to evaluate the safety and reactogenicity of a VEE DNA Vaccine candidate delivered by either intramuscular or intradermal jet injection. The main question it aims to answer is: • Is the VEE DNA Vaccine candidate safe Participants will: * Receive the VEE DNA Vacc...
What is the current status of trial NCT06002503?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2023-10-16. Estimated completion is 2025-05-31.
What conditions does trial NCT06002503 study?
This clinical trial studies the following conditions: Vaccine Reaction.
What interventions are being tested in trial NCT06002503?
The interventions under investigation include: Venezuelan Equine Encephalitis DNA Vaccine (DRUG), PharmaJet Stratis Needle-free Injection System (DEVICE), PharmaJet Tropis Needle-free Injection System (DEVICE).
Who is sponsoring clinical trial NCT06002503?
This trial is sponsored by PharmaJet, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06002503 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaccine Reaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intradermal Influenza Vaccination
RECRUITING · Early Phase 1
-
Understanding Poor Vaccine Responses to Hepatitis B Vaccination
ACTIVE NOT RECRUITING · Phase 4
-
Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
COMPLETED
-
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI